SciSparc Ltd.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.1M
- Price
- $4.43
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.53%
- Volume
- 6.0K
About
SciSparc Ltd. is a pharmaceutical company in the clinical development phase, specializing in creating medications derived from cannabinoid molecules. Their therapeutic pipeline encompasses several key drug candidates: SCI-110, which is being investigated for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease; SCI-160, designed to address pain; and SCI-210, targeting autism spectrum disorder and epilepsy. The company has formed strategic alliances to further its goals. A partnership with Procaps focuses on the development and eventual commercial manufacturing of SCI-110, as well as CannAmide, an oral palmitoylethanolamide in a soft gel capsule. SciSparc is also collaborating with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus. Additionally, it has teamed up with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial, evaluating the safety, tolerability, and effectiveness of SCI-110 for patients experiencing Alzheimer's disease and agitation. Founded in 2004, the company initially operated under the name Therapix Biosciences Ltd. before changing to SciSparc Ltd. in January 2021. Its main corporate office is located in Tel Aviv-Yafo, Israel.
Quick stats
Shares outstanding694.0K
Computed float675.7K
Float / shares97.4%
Cash runway (months)7.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001611746
Websitehttps://scisparc.com
AI Summary
AI-generated1/32
minorbullishoperations update
SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
Three U.S. patent applications were published covering novel combinations of NeuroThera's PEA technology with LSD, ketamine and ibogaine, generated through the ongoing collaboration with Clearmind Medicine.
The applications target potential therapies for depression, PTSD, pain and substance use disorders, building on a prior application covering MDMA-PEA combinations.
For Clearmind, the filings deepen the IP position of the collaboration but remain early-stage applications rather than granted patents or clinical data.